当前位置: X-MOL 学术J. Clin. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.
Journal of Clinical Oncology ( IF 45.3 ) Pub Date : 2020-05-20 , DOI: 10.1200/jco.2020.38.15_suppl.10005
Ines Pires Da Silva 1 , Tasnia Ahmed 2 , Serigne Lo 3 , Irene L.M. Reijers 4 , Alison Weppler 5 , Allison Betof Warner 6 , James Randall Patrinely 7 , Patricio Serra-Bellver 8 , Celeste Lebbe 9 , Joanna Mangana 10 , Khang Nguyen 11 , Lisa Zimmer 12 , Paolo Antonio Ascierto 13 , Dan Stout 14 , Megan Lyle 15 , Oliver Klein 16 , Camille Lea Gerard 17 , Christian U. Blank 4 , Alexander M. Menzies 18 , Georgina V. Long 19
Affiliation  

10005Background: PD1 induces long-term responses in approximately 30% of MM pts, however 2/3 are resistant (innate or acquired) and will require further treatment. A subset of these pts will benefi...

中文翻译:

对 PD1 单药治疗耐药的转移性黑色素瘤 (MM) 患者 (pts) 单独使用 Ipilimumab (IPI) 或与抗 PD-1 (IPI+PD1) 联合使用。

10005背景:PD1 在大约 30% 的 MM pts 中诱导长期反应,但是 2/3 具有耐药性(先天性或后天性)并且需要进一步治疗。这些 pts 的一个子集将受益...
更新日期:2020-05-20
down
wechat
bug